395 related articles for article (PubMed ID: 1596307)
1. The effect of bezafibrate on very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) composition in type 1 diabetes associated with hypercholesterolaemia or combined hyperlipidaemia.
Winocour PH; Durrington PN; Bhatagnar D; Ishola M; Mackness M; Arrol S; Anderson DC
Atherosclerosis; 1992 Mar; 93(1-2):83-94. PubMed ID: 1596307
[TBL] [Abstract][Full Text] [Related]
2. Change in very low-, low-, and high-density lipoproteins during lipid lowering (bezafibrate) therapy: studies in type IIA and type IIb hyperlipoproteinaemia.
Gavish D; Oschry Y; Fainaru M; Eisenberg S
Eur J Clin Invest; 1986 Feb; 16(1):61-8. PubMed ID: 3084275
[TBL] [Abstract][Full Text] [Related]
3. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
Durrington PN; Mackness MI; Bhatnagar D; Julier K; Prais H; Arrol S; Morgan J; Wood GN
Atherosclerosis; 1998 May; 138(1):217-25. PubMed ID: 9678787
[TBL] [Abstract][Full Text] [Related]
4. Abnormalities of VLDL, IDL, and LDL characterize insulin-dependent diabetes mellitus.
Winocour PH; Durrington PN; Bhatnagar D; Ishola M; Arrol S; Mackness M
Arterioscler Thromb; 1992 Aug; 12(8):920-8. PubMed ID: 1637789
[TBL] [Abstract][Full Text] [Related]
5. Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment.
Eisenberg S; Gavish D; Oschry Y; Fainaru M; Deckelbaum RJ
J Clin Invest; 1984 Aug; 74(2):470-82. PubMed ID: 6378975
[TBL] [Abstract][Full Text] [Related]
6. Hyperapobetalipoproteinemia with compositional abnormality of LDL and IDL, a characteristic lipoprotein alteration in essential hypertension.
Ryomoto KI; Suzuki M; Kanazawa A; Hasegawa M; Kimura Y; Yamamura T; Harano Y
Am J Hypertens; 2000 Jun; 13(6 Pt 1):617-24. PubMed ID: 10912744
[TBL] [Abstract][Full Text] [Related]
7. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
[TBL] [Abstract][Full Text] [Related]
8. Effect of bezafibrate treatment on the altered lipoprotein profiles in hypertriglyceridemic subjects.
Norioka M; Suzuki M; Ryomoto K; Ikebuchi M; Harano Y
J Atheroscler Thromb; 2000; 7(4):198-202. PubMed ID: 11521682
[TBL] [Abstract][Full Text] [Related]
9. Influence of early diabetic nephropathy on very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) composition.
Winocour PH; Durrington PN; Bhatnagar D; Ishola M; Mackness M; Arrol S
Atherosclerosis; 1991 Jul; 89(1):49-57. PubMed ID: 1772471
[TBL] [Abstract][Full Text] [Related]
10. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
[TBL] [Abstract][Full Text] [Related]
11. Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia.
Schulzeck P; Bojanovski M; Jochim A; Canzler H; Bojanovski D
Lancet; 1988 Mar; 1(8586):611-3. PubMed ID: 2894548
[TBL] [Abstract][Full Text] [Related]
12. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
[TBL] [Abstract][Full Text] [Related]
13. Effect of combined therapy with bezafibrate and cholestyramine on low-density lipoprotein metabolism in type IIa hypercholesterolemia.
Series JJ; Caslake MJ; Kilday C; Cruickshank A; Demant T; Lorimer AR; Packard CJ; Shepherd J
Metabolism; 1989 Feb; 38(2):153-8. PubMed ID: 2643751
[TBL] [Abstract][Full Text] [Related]
14. Effects of bezafibrate on apolipoprotein B metabolism in type III hyperlipoproteinemic subjects.
Packard CJ; Clegg RJ; Dominiczak MH; Lorimer AR; Shepherd J
J Lipid Res; 1986 Sep; 27(9):930-8. PubMed ID: 3783047
[TBL] [Abstract][Full Text] [Related]
15. Effects of lovastatin on the levels, structure, and atherogenicity of VLDL in patients with moderate hypertriglyceridemia.
Gianturco SH; Bradley WA; Nozaki S; Vega GL; Grundy SM
Arterioscler Thromb; 1993 Apr; 13(4):472-81. PubMed ID: 8385478
[TBL] [Abstract][Full Text] [Related]
16. Effect of dietary treatment on the lipid, lipoprotein and fatty acid compositions in type IV familial hypertriglyceridemia.
Agheli N; Cloarec M; Jacotot B
Ann Nutr Metab; 1991; 35(5):261-73. PubMed ID: 1776822
[TBL] [Abstract][Full Text] [Related]
17. Effects of bezafibrate therapy on subfractions of plasma low-density lipoprotein and high-density lipoprotein, and on activities of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in patients with hyperlipoproteinemia.
Homma Y; Ozawa H; Kobayashi T; Yamaguchi H; Sakane H; Mikami Y; Mikami Y; Nakamura H
Atherosclerosis; 1994 Apr; 106(2):191-201. PubMed ID: 8060379
[TBL] [Abstract][Full Text] [Related]
18. Effects of bezafibrate on lipoprotein subclasses and inflammatory markers in patients with hypertriglyceridemia--a nuclear magnetic resonance study.
Ikewaki K; Noma K; Tohyama J; Kido T; Mochizuki S
Int J Cardiol; 2005 Jun; 101(3):441-7. PubMed ID: 15907413
[TBL] [Abstract][Full Text] [Related]
19. An increased number of very-low-density lipoprotein particles is strongly associated with coronary heart disease in Japanese men, independently of intermediate-density lipoprotein or low-density lipoprotein.
Koba S; Hirano T; Sakaue T; Takeuchi H; Adachi M; Katagiri T
Coron Artery Dis; 2002 Aug; 13(5):255-62. PubMed ID: 12394649
[TBL] [Abstract][Full Text] [Related]
20. Effects of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia.
Mackness MI; Bhatnagar D; Durrington PN; Prais H; Haynes B; Morgan J; Borthwick L
Eur J Clin Nutr; 1994 Dec; 48(12):859-65. PubMed ID: 7889894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
